Global Hormone Replacement Therapy research
Global Hormone Replacement Therapy research

Hormone Replacement Therapy Comprehensive Study by Type (Estrogen replacement therapy, Growth hormone replacement therapy, Thyroid Hormone Replacement Therapy, Testosterone Hormone Replacement Therapy), Application (Oral, Parenteral, Transdermal) Players and Region - Global Market Outlook to 2025

Hormone Replacement Therapy Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Sep 2020 Edition 237 Pages 165 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Hormone Replacement Therapy Market Scope
The global Hormone Replacement Therapy market is expected to witness high demand in the forecasted year due to a rise in the number of people suffering from hormonal imbalance disorders. Hormone Replacement Therapy is the most adopted treatment method mainly used in oral medication is the most effective. Owing to the innovation in various technologies, patients are switching from conventional treatments to specialized hormone replacement therapy treatments as the results are more effective. Additionally, Hormone replacement therapy includes estrogen replacement therapy, growth hormone replacement therapy, thyroid hormone replacement therapy, testosterone hormone replacement therapy. These factors mentioned above boost the growth of the global market.

The market study is segmented by Type (Estrogen replacement therapy, Growth hormone replacement therapy, Thyroid Hormone Replacement Therapy and Testosterone Hormone Replacement Therapy), by Application (Oral, Parenteral and Transdermal) and major geographies with country level break-up.

The global Hormone Replacement Therapy market is highly competitive. to survive in the competitive market, key players adopted advanced healthcare technology for improved healthcare services. Furthermore, in order to retain market share and diversify its product portfolio, major players often adopt strategies such as mergers, acquisitions, and new product launches. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Hormone Replacement Therapy market throughout the predicted period.

F. Hoffmann-La Roche AG (Switzerland), Merck Serono (Germany), Novartis International AG (Switzerland), Novo Nordisk A/S (Denmark), Pfizer Inc. (United States), Abbott Laboratories (United States), ANI Pharmaceuticals (United States), Eli Lilly and Company (United States) and Hisamitsu Pharmaceutical Co., Ltd. (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Merck & Co., Inc. (United States) and Mylan N.V.(United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Hormone Replacement Therapy market by Type, Application and Region.

On the basis of geography, the market of Hormone Replacement Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In Dec 2019, Pfizer Inc. confirmed that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application to treat prostate cancer. The treatment, Xtandi, helps patients with metastatic hormone-sensitive prostate cancer (mCSPC). This type of prostate cancer spreads to other parts of the body.


Market Trend
  • Technological Advancements in the Field of Drug Delivery Systems

Market Drivers
  • Rising Incidences of Hormonal Imbalance Disorders
  • Increases the Range of Menopausal Window

Opportunities
  • Rising Awareness among the Consumers
  • Increasing Focus of Healthcare Providers on the Eradication of Hormonal Deficiencies

Restraints
  • High Cost of Therapies

Challenges
  • Lack of Awareness in Underdeveloped Countries
  • Side Effects of Therapies


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analyst and Strategic Business Planners, Government Regulatory and Research Organizations and End-Use Industries

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Estrogen replacement therapy
  • Growth hormone replacement therapy
  • Thyroid Hormone Replacement Therapy
  • Testosterone Hormone Replacement Therapy
By Application
  • Oral
  • Parenteral
  • Transdermal
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidences of Hormonal Imbalance Disorders
      • 3.2.2. Increases the Range of Menopausal Window
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness in Underdeveloped Countries
      • 3.3.2. Side Effects of Therapies
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in the Field of Drug Delivery Systems
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hormone Replacement Therapy, by Type, Application and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Hormone Replacement Therapy (Value)
      • 5.2.1. Global Hormone Replacement Therapy by: Type (Value)
        • 5.2.1.1. Estrogen replacement therapy
        • 5.2.1.2. Growth hormone replacement therapy
        • 5.2.1.3. Thyroid Hormone Replacement Therapy
        • 5.2.1.4. Testosterone Hormone Replacement Therapy
      • 5.2.2. Global Hormone Replacement Therapy by: Application (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Parenteral
        • 5.2.2.3. Transdermal
      • 5.2.3. Global Hormone Replacement Therapy Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Hormone Replacement Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck Serono (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis International AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novo Nordisk A/S (Denmark)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abbott Laboratories (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ANI Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Hisamitsu Pharmaceutical Co., Ltd. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Hormone Replacement Therapy Sale, by Type, Application and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Hormone Replacement Therapy (Value)
      • 7.2.1. Global Hormone Replacement Therapy by: Type (Value)
        • 7.2.1.1. Estrogen replacement therapy
        • 7.2.1.2. Growth hormone replacement therapy
        • 7.2.1.3. Thyroid Hormone Replacement Therapy
        • 7.2.1.4. Testosterone Hormone Replacement Therapy
      • 7.2.2. Global Hormone Replacement Therapy by: Application (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Parenteral
        • 7.2.2.3. Transdermal
      • 7.2.3. Global Hormone Replacement Therapy Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hormone Replacement Therapy: by Type(USD Million)
  • Table 2. Hormone Replacement Therapy Estrogen replacement therapy , by Region USD Million (2014-2019)
  • Table 3. Hormone Replacement Therapy Growth hormone replacement therapy , by Region USD Million (2014-2019)
  • Table 4. Hormone Replacement Therapy Thyroid Hormone Replacement Therapy , by Region USD Million (2014-2019)
  • Table 5. Hormone Replacement Therapy Testosterone Hormone Replacement Therapy , by Region USD Million (2014-2019)
  • Table 6. Hormone Replacement Therapy: by Application(USD Million)
  • Table 7. Hormone Replacement Therapy Oral , by Region USD Million (2014-2019)
  • Table 8. Hormone Replacement Therapy Parenteral , by Region USD Million (2014-2019)
  • Table 9. Hormone Replacement Therapy Transdermal , by Region USD Million (2014-2019)
  • Table 10. South America Hormone Replacement Therapy, by Country USD Million (2014-2019)
  • Table 11. South America Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 12. South America Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 13. Brazil Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 14. Brazil Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 15. Argentina Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 16. Argentina Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 17. Rest of South America Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 18. Rest of South America Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 19. Asia Pacific Hormone Replacement Therapy, by Country USD Million (2014-2019)
  • Table 20. Asia Pacific Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 21. Asia Pacific Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 22. China Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 23. China Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 24. Japan Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 25. Japan Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 26. India Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 27. India Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 28. South Korea Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 29. South Korea Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 30. Taiwan Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 31. Taiwan Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 32. Australia Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 33. Australia Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 34. Rest of Asia-Pacific Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 35. Rest of Asia-Pacific Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 36. Europe Hormone Replacement Therapy, by Country USD Million (2014-2019)
  • Table 37. Europe Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 38. Europe Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 39. Germany Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 40. Germany Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 41. France Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 42. France Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 43. Italy Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 44. Italy Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 45. United Kingdom Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 46. United Kingdom Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 47. Netherlands Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 48. Netherlands Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 49. Rest of Europe Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 50. Rest of Europe Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 51. MEA Hormone Replacement Therapy, by Country USD Million (2014-2019)
  • Table 52. MEA Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 53. MEA Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 54. Middle East Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 55. Middle East Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 56. Africa Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 57. Africa Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 58. North America Hormone Replacement Therapy, by Country USD Million (2014-2019)
  • Table 59. North America Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 60. North America Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 61. United States Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 62. United States Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 63. Canada Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 64. Canada Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 65. Mexico Hormone Replacement Therapy, by Type USD Million (2014-2019)
  • Table 66. Mexico Hormone Replacement Therapy, by Application USD Million (2014-2019)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Hormone Replacement Therapy: by Type(USD Million)
  • Table 77. Hormone Replacement Therapy Estrogen replacement therapy , by Region USD Million (2020-2025)
  • Table 78. Hormone Replacement Therapy Growth hormone replacement therapy , by Region USD Million (2020-2025)
  • Table 79. Hormone Replacement Therapy Thyroid Hormone Replacement Therapy , by Region USD Million (2020-2025)
  • Table 80. Hormone Replacement Therapy Testosterone Hormone Replacement Therapy , by Region USD Million (2020-2025)
  • Table 81. Hormone Replacement Therapy: by Application(USD Million)
  • Table 82. Hormone Replacement Therapy Oral , by Region USD Million (2020-2025)
  • Table 83. Hormone Replacement Therapy Parenteral , by Region USD Million (2020-2025)
  • Table 84. Hormone Replacement Therapy Transdermal , by Region USD Million (2020-2025)
  • Table 85. South America Hormone Replacement Therapy, by Country USD Million (2020-2025)
  • Table 86. South America Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 87. South America Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 88. Brazil Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 89. Brazil Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 90. Argentina Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 91. Argentina Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 92. Rest of South America Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 93. Rest of South America Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 94. Asia Pacific Hormone Replacement Therapy, by Country USD Million (2020-2025)
  • Table 95. Asia Pacific Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 96. Asia Pacific Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 97. China Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 98. China Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 99. Japan Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 100. Japan Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 101. India Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 102. India Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 103. South Korea Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 104. South Korea Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 105. Taiwan Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 106. Taiwan Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 107. Australia Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 108. Australia Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 109. Rest of Asia-Pacific Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 110. Rest of Asia-Pacific Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 111. Europe Hormone Replacement Therapy, by Country USD Million (2020-2025)
  • Table 112. Europe Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 113. Europe Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 114. Germany Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 115. Germany Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 116. France Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 117. France Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 118. Italy Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 119. Italy Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 120. United Kingdom Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 121. United Kingdom Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 122. Netherlands Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 123. Netherlands Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 124. Rest of Europe Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 125. Rest of Europe Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 126. MEA Hormone Replacement Therapy, by Country USD Million (2020-2025)
  • Table 127. MEA Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 128. MEA Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 129. Middle East Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 130. Middle East Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 131. Africa Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 132. Africa Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 133. North America Hormone Replacement Therapy, by Country USD Million (2020-2025)
  • Table 134. North America Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 135. North America Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 136. United States Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 137. United States Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 138. Canada Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 139. Canada Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 140. Mexico Hormone Replacement Therapy, by Type USD Million (2020-2025)
  • Table 141. Mexico Hormone Replacement Therapy, by Application USD Million (2020-2025)
  • Table 142. Research Programs/Design for This Report
  • Table 143. Key Data Information from Secondary Sources
  • Table 144. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hormone Replacement Therapy: by Type USD Million (2014-2019)
  • Figure 5. Global Hormone Replacement Therapy: by Application USD Million (2014-2019)
  • Figure 6. South America Hormone Replacement Therapy Share (%), by Country
  • Figure 7. Asia Pacific Hormone Replacement Therapy Share (%), by Country
  • Figure 8. Europe Hormone Replacement Therapy Share (%), by Country
  • Figure 9. MEA Hormone Replacement Therapy Share (%), by Country
  • Figure 10. North America Hormone Replacement Therapy Share (%), by Country
  • Figure 11. Global Hormone Replacement Therapy share by Players 2019 (%)
  • Figure 12. Global Hormone Replacement Therapy share by Players (Top 3) 2019(%)
  • Figure 13. Global Hormone Replacement Therapy share by Players (Top 5) 2019(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 16. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2019
  • Figure 17. Merck Serono (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Merck Serono (Germany) Revenue: by Geography 2019
  • Figure 19. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Novartis International AG (Switzerland) Revenue: by Geography 2019
  • Figure 21. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 22. Novo Nordisk A/S (Denmark) Revenue: by Geography 2019
  • Figure 23. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 25. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott Laboratories (United States) Revenue: by Geography 2019
  • Figure 27. ANI Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 28. ANI Pharmaceuticals (United States) Revenue: by Geography 2019
  • Figure 29. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 30. Eli Lilly and Company (United States) Revenue: by Geography 2019
  • Figure 31. Hisamitsu Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Hisamitsu Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2019
  • Figure 33. Global Hormone Replacement Therapy: by Type USD Million (2020-2025)
  • Figure 34. Global Hormone Replacement Therapy: by Application USD Million (2020-2025)
  • Figure 35. South America Hormone Replacement Therapy Share (%), by Country
  • Figure 36. Asia Pacific Hormone Replacement Therapy Share (%), by Country
  • Figure 37. Europe Hormone Replacement Therapy Share (%), by Country
  • Figure 38. MEA Hormone Replacement Therapy Share (%), by Country
  • Figure 39. North America Hormone Replacement Therapy Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • F. Hoffmann-La Roche AG (Switzerland)
  • Merck Serono (Germany)
  • Novartis International AG (Switzerland)
  • Novo Nordisk A/S (Denmark)
  • Pfizer Inc. (United States)
  • Abbott Laboratories (United States)
  • ANI Pharmaceuticals (United States)
  • Eli Lilly and Company (United States)
  • Hisamitsu Pharmaceutical Co., Ltd. (Japan)
Additional players considered in the study are as follows:
Merck & Co., Inc. (United States) , Mylan N.V.(United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation